AIVITA Biomedical, Inc.

AIVITA Biomedical is a biotechnology company specializing in personalized vaccines and autologous cell-based therapies for cancer treatment, infectious disease prevention, and vision loss. The company employs a pan-antigenic approach targeting all neoantigens in cancer vaccines to overcome tumor mutation resistance. Lead product AV-GBM-1 is an autologous dendritic cell immunotherapy in Phase III trials for glioblastoma multiforme. Additional pipeline includes AV-MEL-1 for metastatic melanoma, a personalized multi-pathogen vaccine kit for emerging infectious disease prevention, and stem cell therapies for retinal degeneration. AIVITA's proprietary autologous cell therapy platform and stem cell differentiation expertise enable safe and economical manufacturing of personalized immunotherapeutic solutions across oncology, infectious disease, and ophthalmology indications.